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ABSTRACT: Signal transducer and activator of transcription 3 (STAT3) is an oncogenic transcription factor that has been implicated in many human 
cancers and has emerged as an ideal target for cancer therapy. Withaferin A (WFA) is a natural product with promising antiproliferative properties through 
its association with a number of molecular targets including STAT3. However, the effect of WFA in pediatric neuroblastoma (NB) and its interaction with 
STAT3 have not been reported. In this study, we found that WFA effectively induces dose-dependent cell death in high-risk and drug-resistant NB as well 
as multiple myeloma (MM) tumor cells, prevented interleukin-6 (IL-6)–mediated and persistently activated STAT3 phosphorylation at Y705, and blocked 
the transcriptional activity of STAT3. We further provide computational models that show that WFA binds STAT3 near the Y705 phospho-tyrosine resi-
due of the STAT3 Src homology 2 (SH2) domain, suggesting that WFA prevents STAT3 dimer formation similar to BP-1-102, a well-established STAT3 
inhibitor. Our findings propose that the antitumor activity of WFA is mediated at least in part through inhibition of STAT3 and provide a rationale for 
further drug development and clinical use in NB and MM.
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Introduction
Proteins of the signal transducer and activator of transcrip-
tion (STAT) family promote tumor proliferation, differen-
tiation, apoptosis, metastasis, invasion, and angiogenesis. 
In addition, STAT proteins contribute to inflammation and 
immune response and promote chemo- and radioresistance.1–5 
Particularly STAT3 is a key regulator of these processes 
and is often constitutively activated or overexpressed, thus 
making this protein a promising target in many solid and 
hematopoietic human cancers.6,7 STAT3 was initially discov-
ered as a transcription factor induced by interferon-gamma   
(IFN-γ)8,9 and since it is required for the oncogenic transfor-
mation activity of v-src, STAT3 is considered an oncogene.10 
The phosphorylation of STAT3 at residue Y705 triggers 
STAT3 dimerization, which is required for its translocation 
to the nucleus where it binds DNA and exhibits its transcrip-
tional activity. A second phosphorylation event at residue S727 
is required for optimal transcriptional activity.11 Aberrant 
activation of STAT3 can trigger the initiation, development, 
and progression of human tumors through STAT3-depen-
dent activation of downstream genes that regulate apoptosis, 
cell cycle, and angiogenesis.12 Cytokines of the interleukin-6   Yco et al
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(IL-6) family, including IL-6, oncostatin M, and leukemia 
inhibitory factor, activate a number of signaling pathways 
including STAT3 through JAK1 and JAK2,13,14 which play a 
major role in the communication between tumor and immune 
cells.2
Neuroblastoma (NB) is a pediatric cancer of the sympa-
thetic nervous system and the most common extra-cranial solid 
malignancy.15 While significant therapeutic success has been 
achieved over the past 60 years, the improvement in overall sur-
vival rates is mostly limited to low- and intermediate-risk NB 
patients, while the treatment of aggressive, high-risk NB patients 
with multiple relapse and refractory disease remains a significant 
therapeutic challenge. Unlike in most cancers, STAT3 in NB 
cell lines is typically not constitutively active but can be activated 
through the influence of the micro-environment, for example 
IL-6, which is not produced by NB cells but by bone marrow–
derived mesenchymal stem cells as well as tumor-associated 
macrophages.16 Indeed, elevated levels of IL-6 in the bone mar-
row and peripheral blood have been linked to poor prognosis in 
high-risk NB patients and cell culture studies confirmed that 
IL-6 increased the proliferation and decreased cytotoxic drug–
induced apoptosis in response to IL-6–mediated STAT3 activa-
tion in NB cells.16,17 Increased and persistent STAT3 activity 
is commonly detected in hematopoietic malignancies such as 
multiple myeloma (MM), leukemia, and lymphoma. MM is a 
cancer of plasma cells that accumulate in the bone marrow and 
interfere with the production of normal blood cells.
The discovery and isolation of potent anticancer com-
pounds from nature has produced some impressive results 
in the past, and a respectful number of drugs on the mar-
ket today are natural products or natural product–inspired 
derivatives.18,19 Withaferin A (WFA) (Fig. 1) was originally 
isolated from the plant Withania somnifera and showed anti-
proliferative properties in several cancer types. A number of 
potential targets for WFA have been identified (reviewed in)20 
but few have been characterized in more detail and shown to 
bind directly to WFA. While STAT3 activity inhibition has 
been investigated in both NB and MM,14,16,21 the antitumor 
effects of WFA in NB and its impact on STAT3 activity has 
never been examined. To our knowledge, only one study exists 
that reported the effect of WFA on nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB) in MM.22
The present study was designed to test if WFA induces 
death of NB and MM tumor cells in the presence or absence of 
IL-6 and to verify if WFA directly binds STAT3. We propose 
that WFA ablates STAT3 transcriptional activity by prevent-
ing dimerization which leads to tumor growth inhibition. This 
proof-of-concept demonstrates that blockade of STAT3 sig-
naling may be of therapeutic benefit for NB and MM patients.
Experimental Procedures
Mammalian cell cultures and reagents. The human 
NB cell lines Be(2)-c, SMS-KCNR, and SH-SY5Y were 
obtained from Dr Giselle Sholler (DeVos Children’s Hospital, 
Grand Rapids, MI). The NB cell line LAN-5 was obtained 
from Dr Randy Wada (John A. Burns School of Medicine, 
  Honolulu, HI). NB cell line IMR-32 was purchased from 
American Type Culture (Collection, Manassas, VA). MM 
cell lines MM1.RL and U266 were obtained from Dr Nancy 
L. Krett (Northwestern University, Chicago, IL). Cells were 
maintained in RPMI 1640 (Mediatech Inc, Manassas, VA) 
containing 10% heat-inactivated fetal bovine serum (FBS) 
(Atlanta Biologicals, Inc, Lawrenceville, GA), penicillin 
(100 IU/mL), and streptomycin (100 Ag/mL) (Mediatech). 
Stock solutions were prepared for WFA at 42.5 mM (Enzo 
Life Sciences, Inc, Farmingdale, NY) and for S3I-201 at 
54.7 mM (Selleck Chemicals, Houston, TX) in dimethyl sulf-
oxide (DMSO) (Electron Microscopy Sciences, Hatfield, PA). 
Recombinant human IL-6 (5.0 μg/mL) (PeproTech, Rocky 
Hill, NJ) was dissolved in 1X phosphate-buffered saline (PBS) 
and 0.1% bovine serum albumin. WFA, S3I-201, and IL-6 
were diluted with culture media before addition to cells. An 
equal concentration of DMSO was used for control treatments.
Western blot analysis. Lysates from WFA- or S3I-201–
treated cells and DMSO-treated (control) cells were prepared 
using the radioimmunoprecipitation assay (RIPA) buffer 
(20 mM Tris–HCl [pH 7.5], 0.1% [w/v] sodium lauryl sul-
fate, 0.5% [w/v] sodium deoxycholate, 135 mM NaCl, 1% 
Figure 1. The structure of WFA. (A) Two-dimensional structure formula 
of WFA, an ergostane-type steroid (5β,6β-epoxy-4β,27-dihydroxy-1-oxo-
22R-witha-2,24-dienolide, MW of 470.6). Atom stereo labels (R) and (S) as 
well as numbering for key atoms are shown in red. (B) Four diverse three-
dimensional conformers, displayed according to optimal structural views. 
the corresponding mmF94 energies are 113.73, 118.87, 121.07, and 127.12 
and kcal/mol, respectively. Selected atoms and oxygen are colored red.Withaferin A inhibits STAT3 in NB and MM cells
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[v/v] Triton X-100, 10% [v/v] glycerol, 2 mM ethylenediami-
netetraacetic acid (EDTA), supplemented with Complete 
Protease Inhibitor Cocktail, EDTA-free (EMD Millipore, 
Billerica, MA) and phosphatase inhibitors (20 mM sodium 
fluoride, and 0.27 mM sodium vanadate). Lysate samples were 
suspended by rotation at 4°C for a minimum of 30 minutes 
and clarified by centrifugation for 10 minutes at 15,000 rpm 
at 4°C. The supernatant was stored at -20°C until further 
use. Total protein concentration was determined by Bradford 
dye reagent protein assay (Bio-Rad Laboratories Inc, Rich-
mond, CA). Laemmli buffer (Bio-Rad) containing 10% (v/v) 
β-mercaptoethanol (EMD Millipore) was added to the lysates 
and boiled for 5 minutes. Twenty micrograms of total protein 
was resolved by 8% sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis and electrotransferred onto polyvinylidene 
difluoride membranes (Bio-Rad). Membranes were blocked 
with 5% nonfat dry milk (Santa Cruz Biotechnology, Santa 
Cruz, CA) in 1X Tris-buffered solution and 0.1% Tween-20 
(0.1% T-TBS) for 1 hour at room temperature. The mem-
branes were washed with 0.1% T-TBS and incubated over-
night at 4°C with rabbit polyclonal phospho-STAT3 (Y705), 
rabbit polyclonal phospho-STAT3 (S727), rabbit polyclonal 
STAT3, or rabbit monoclonal α-tubulin primary antibodies 
(Cell Signaling Technology, Inc., Danvers, MA). After three 
5-minute washes in 0.1% T-TBS, membranes were incubated 
for 1 hour at room temperature in a fluorescently labeled mix-
ture of secondary goat anti-rabbit antibodies (IRDye 800CW 
or IRDye 680RD; LI-COR Biosciences, Lincoln, NE). Pro-
tein bands were detected using Odyssey Infrared Imaging 
System (LI-COR).
Cell viability assay. Live/dead cells were determined as 
follows: cells were cultured in 96-well microtiter plates (Greiner 
Bio-One Inc, Monroe, NC). All cell lines were suspended in 
0.09 mL of medium per well. NB cell lines were seeded at a 
concentration of 2.0 × 104 cells per well, except NB cell line 
Be(2)-c, which was seeded at 7.0 × 103 cells per well. MM cell 
lines were seeded at 2.5 × 104 cells per well. After overnight 
incubation, cells were treated with increasing concentrations 
of WFA (0–10 μM) or S3I-201 (0–100 μM) for 48 hours. 
An equal concentration of DMSO was used as a control. 
After treatment, 0.5 μg/mL Hoechst 332558 (Biotium, Inc, 
Hayward, CA) and 0.5 μM TOTO-3 Iodide (Life Technolo-
gies, Grand Island, NY) were added in each well and incubated 
for 10 minutes. Hoechst 332558 is a plasma membrane–per-
meant dye that labels all cell nuclei in a population. TOTO-3 
Iodide, on the other hand, is a plasma membrane–impermeant 
dye that specifically labels dying and dead cells. Cell viabil-
ity was measured with the Operetta High Content Imaging 
System (PerkinElmer, Waltham, MA) using the image analy-
sis mode “Ready-Made Solution Live/Dead Cell Counting” 
from the Harmony Database. Briefly, cell count was done 
for the two subpopulations: live and dead. The threshold was 
assigned to filter out cells at the dead stain background level. 
Then, the mode “Select   population building block, with the 
adjusted threshold” was used to identify cells with significant 
dead cell marker intensity. Finally, the percentage (%) of dead 
cells in the cell population was calculated [(dead stain posi-
tive—number of objects/nuclei—number of objects) × 100]. 
The Microsoft Excel spreadsheet software (Redmund, WA) 
was used to calculate the mean and the standard error of the 
mean (SEM) of three independent experiments.
Preparation of nuclear extracts. The preparation of 
nuclear extracts from cells treated with WFA, S3I-201, or 
DMSO (control) was carried out with the TransAM STAT3 
Transcription Factor Assay kit (Active Motif, Carlsbad, CA), 
following the manufacturer’s protocol. Briefly, MM1.RL and 
U266 cells (4.0 × 106 cells) were seeded in six-well culture 
plate. Cells were serum-starved (RPMI 1640 media contain-
ing 0.1% FBS) overnight and treated with WFA (5 μM) or 
S3I-201 (100 μM) for 5 hours. After treatment, MM1.RL 
cells were stimulated with IL-6 (4 ng/mL) for 1 hour. Cells 
were then washed and collected using ice-cold 1X PBS/
PBS supplemented with phosphatase inhibitor buffer. Cells 
were pelleted by centrifugation for 5 minutes at 300 × g and 
4°C. Cells were resuspended in ice-cold hypotonic buffer 
(20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 5 mM sodium fluoride, 10 μM sodium molybdate, 
and 0.1 mM EDTA) and incubated on ice for 15 minutes. 
Nonidet P-40 (final concentration of 0.5%) was mixed into the 
samples and centrifuged for 30 seconds at 4°C. Finally, the 
nuclear pellet was resuspended in Complete Binding Buffer by 
rotation at 4°C for 30 minutes and centrifuged for 10 minutes 
at 14,000 × g at 4°C, saving the supernatant (nuclear cell 
extract). Protein concentration was determined by Bradford 
dye reagent protein assay (Bio-Rad).
STAT3 transcription factor assay. STAT3 transcrip-
tion factor activation was detected and quantified in nuclear 
cell extracts with the TransAM STAT3 Transcription Fac-
tor Assay kit (Active Motif), following the manufacturer’s 
protocol. This kit is based on a DNA-binding enzyme-linked 
immunosorbent assay (ELISA). In brief, equal amounts of 
nuclear extracts from cells treated with WFA, S3I-201, 
or DMSO (control) were added to a 96-stripwell microti-
ter plate (provided by the kit) to which a STAT3-specific, 
consensus-binding site oligonucleotide has been immobi-
lized and incubated for 1 hour at room temperature with 
mild shaking. At the same time a competitive binding con-
trol experiment was performed using either wild-type (WT) 
or mutant (MT) oligonucleotide AM6, provided by the 
manufacturer. WT oligonucleotide AM6 is a competitor for 
STAT binding, while the MT oligonucleotide AM6 oligo-
nucleotide has no effect on STAT binding. After incubation, 
wells were washed three times with wash buffer. A STAT3 
antibody which is specific for the epitope on the bound and 
active form of STAT3 was diluted in Antibody-binding buf-
fer, added to each well, and incubated for 1 hour at room 
temperature. Afterward, wells were washed and incubated 
with horseradish   peroxidase (HRP)-conjugated antibody for Yco et al
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1 hour at room   temperature. Developing solution was then 
added to each well and incubated for 2–10 minutes at room 
temperature protected from direct light. The reaction was 
stopped by adding stop solution. Finally, absorbance was 
measured at 450 nm using a Synergy Mx Monochromator-
Based Multi-Mode Microplate Reader (BioTek Instruments, 
Inc, Winooski, VT). A nuclear extract from IL-6–stimu-
lated (100 ng/mL) HepG2 cells served as a positive control. 
Optical density (OD) readings, representing STAT3 tran-
scription factor activation, were calculated and evaluated 
using the Microsoft Excel spreadsheet software.
Protein–ligand docking. Atomic coordinates from X-ray 
crystal structures of protein transcription factor STAT3 were 
retrieved from the Protein Data Bank23 and used for ligand-
docking studies. The nonphosphorylated STAT3 core fragment 
comprised residues V136-R688 (pdb:3cwgA/3cwgB, dimer) 
and residues V136-F716 (pdb:4e68A, monomer, in complex 
with DNA) whereas the Y705 phosphorylated protein con-
sisted of residues V136-F716 (pdb:1bg1A, monomer, in com-
plex with DNA). To expand the coordinates of the monomeric 
subunits of 1bg1 and 4e68 to their dimer subunits, the coordi-
nates of the dimers were calculated from the BIOMT transfor-
mation matrices contained in the pdb files.
WFA (Compound ID: 265237) structure information and 
descriptive data sets were obtained from the PubChem Substance 
and Compound Database.24 Three-dimensional coordinates 
were available for four diverse conformers, energy minimized by 
the MMFF94 force field.25 To explore other conformations in 
ligand recognition, we also subjected WFA to local energy mini-
mization using the robust Dreiding force field.26
Docking was carried out to find the possible locations, ori-
entation, and interactions of the WFA-binding sites in STAT3. 
GRAMM, the original Global Range Molecular Matching 
method was used on our local host both in high-resolution geo-
metric docking mode27,28 and in low-resolution semi-flexible 
mode to account for conformational flexibility.29,30 The algo-
rithm predicts the binding pockets by computing the intermo-
lecular energy potential in protein–ligand complexes through 
an exhaustive multidimensional search of translations and rota-
tions of the components and using correlation techniques with 
Fast Fourier transform.
The docking simulations were run with every possible 
permutation of the phosphorylated and nonphosphorylated 
monomers and dimers in complexes with the four canonical 
and the local energy–minimized WFA conformers, and in the 
presence and absence of bound DNA as the available three-
dimensional data permitted. Altogether 100 sets (50 geomet-
ric and 50 semi-flexible) were screened for the binding sites 
and the first 20 binding locations of each set were scored by 
the number of occurrences of residues in the contact areas 
among the various protein–ligand pairs. The spatially most 
invariant complexes were selected as the most probable mod-
els. The predicted binding sites were visualized and analyzed 
with the ICM-Browser (Molsoft LLC, San Diego, CA, USA). 
  Chemical structure drawing was performed employing the 
ICM Molecular Editor.
Results
WFA induces dose-dependent cell death in NB 
and MM. To investigate if WFA induces cell death in cell 
cultures of NB and MM, we tested increasing drug concen-
trations against a panel of tumor cell lines. To our knowledge, 
WFA has not been studied in NB, and only one report was 
found evaluating WFA in MM cells.22 As shown in Figure 2, 
WFA induced cell death in seven tumor cell lines in a dose-
dependent manner between 0 and 10 μM, with inhibitory 
activity detected as low as 0.625 μM, in IMR-32 NB cells. 
At 10 μM, cell death was significant in all tested tumor cell 
lines and ranged from ~40% to 90%, depending on individual 
lines (Fig. 2A). Importantly, WFA also impeded the growth 
of chemotherapy treatment–resistant Be(2)-c, SMS-KCNR, 
and MM1.RL tumor cells as well as of U266 cells harbor-
ing persistently activated STAT3. For direct comparison, the 
STAT3 inhibitor S3I-201 (see Supplementary Fig. 1) was used 
and revealed that about 10-fold higher drug concentrations 
were required to achieve comparable results, under identical 
experimental conditions (Fig. 2B). Furthermore, S3I-201 did 
not exert any antiproliferative effects on chemotherapy-resis-
tant MM1.RL cells, even at the highest drug concentrations 
(100 μM) while WFA induced about 50% cell death in this 
cell line at 10 μM.
Additional studies were performed at the National 
Cancer Institute (NCI) with the standard NCI 60 cell line 
panel and confirmed that WFA exhibits broad-range, dose-
dependent potency in many tumor types including leukemia, 
non–small cell lung cancer, colon cancer, central nervous sys-
tem (CNS) cancer, melanoma, ovarian cancer, renal cancer, 
prostate cancer, and breast cancer (see Supplementary Fig. 2), 
thus rendering WFA an interesting anticancer agent with 
broad application potential.
WFA suppresses STAT3 phosphorylation in NB and 
MM. Because WFA binds to the protein near the Y705 phos-
pho-tyrosine residue of the STAT3 Src homology 2 (SH2) 
domain and prevents STAT3 dimer formation in silico (Fig. 3), 
we examined whether WFA interferes with STAT3 phos-
phorylation at Y705 in vivo, thus providing a possible mecha-
nism for the observed induction of cell death (Fig. 2). Since 
phosphorylation at S727 enhances STAT3 transcriptional 
regulatory activities,31 we tested both phosphorylation sites. 
STAT3 inhibitor S3I-201 was included as control for direct 
comparison. In NB cells, the phosphorylation of STAT3 at 
Y705 was detected in IMR-32 and LAN-5 control cells and 
was reduced in response to treatment with WFA and S3I-
201 (Fig. 3A). Phosphorylation of STAT3 at S727 was only 
observed in LAN-5 cells. In MM cells, phosphorylation of 
STAT3 at Y705 and S727 was significantly reduced compared 
to U266 control cells, which expresses persistently activated 
STAT3 (Fig. 3B). In some cell lines, total STAT3 levels also Withaferin A inhibits STAT3 in NB and MM cells
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Figure 2. WFA induces cell death in NB and MM. Cell viability analysis of NB cell lines (Be(2)-c, SMS-KCNR, SH-SY5Y, IMR-32, and LAN-5) and 
MM cell lines (MM1.RL and U266) treated with increasing concentrations of (A) WFA (0–10 μM) or (B) S3I-201 (0–100 μM) for 48 hours. Cells were 
stained with Hoechst 332558 (blue) and TOTO-3 Iodide (red) to distinguish live and dead cells, respectively. Data are representative of three individual 
experiments (n = 3); bars, mean ± sem.
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decreased in the presence of S3I-201 and/or WFA, suggesting 
that both inhibitors exert STAT3 phosphorylation–indepen-
dent effects that induce cell death. In cell lines where tubulin 
was reduced, a more general cell death mechanism might be 
triggered in response to an overall protein shutdown.
WFA inhibits IL-6–mediated and persistent STAT3 
activation in MM cells. Since IL-6 induction is known to 
trigger STAT3 activation in MM cells, we treated MM1.RL 
cells with WFA at various time points, followed by IL-6 treat-
ment for 1 hour. IL-6 strongly induced STAT3 phosphoryla-
tion at Y705 but not S727 and was inhibited by WFA after only 
2 hours of incubation (Fig. 4A); however, total STAT3 levels 
were reduced after exposure of cells to WFA for more than 
4 hours, suggesting that WFA also downregulates STAT3 
protein if cells are exposed to the drug for longer time periods. 
In persistently activated U266 cells, WFA reduced STAT3 
phosphorylation in a time-dependent manner without sig-
nificantly altering total STAT3 levels up to 6 hours (Fig. 4B). 
Total STAT3 levels declined at drug exposure times beyond 
10 hours. WFA efficiently blocked STAT3 phosphorylation at 
Y705 in both nuclear and cytosolic extracts of IL-6–induced 
MM1.RL and persistently activated U266 cells. Total STAT3 
protein levels declined in the cytosolic extracts but stayed the 
same or slightly increased in the nuclear extracts, after WFA 
treatment (Fig. 4C).
Next we examined the effect of WFA on the transcrip-
tional activity of STAT3 using a highly sensitive DNA-binding 
ELISA assay that measures STAT3 transcription factor acti-
vation. The STAT3 transcriptional activity in nuclear extracts 
of IL-6–induced MM1.RL cells and persistently activated 
U266 cells was strongly inhibited by WFA at 5 μM which 
was comparable to effects achieved by STAT3 inhibitor S3I-
201 at 100 μM (Fig. 4D).
Computational modeling and docking of WFA into 
STAT3. To examine if WFA binds STAT3, we performed 
extensive computational modeling and docking simulations. 
WFA, a potential anticancer withanolide, is a cell-permeable 
steroidal lactone with a modified ergostane framework whose 
molecular structure is shown in Figure 1A. It has four dis-
tinct canonical conformers separated by energy barriers higher 
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Figure 4. effect of WFA on constitutive and iL-6–induced stAt3 transcriptional activation and translocation in mm. Western blot analysis of p-stAt3 
(Y705 and S727) and total STAT3 from whole-cell lysates of (A) MM1.RL and (B) U266 cells (4.0 × 106 cells) treated with WFA (10 μM) for indicated 
times with or without IL-6 stimulation (4 ng/mL) for 1 hour. (C) STAT3 nuclear translocation analysis from prepared cytosol extract (C.E.), nuclear extract 
(N.E.), and whole-cell lysate (W.C.) of MM1.RL and U266 cells treated with WFA (5 μM) for 5 hours with or without IL-6 stimulation (4 ng/mL) for 1 hour. 
(D) STAT3 transcriptional activity assay using the nuclear extract from MM cells treated with WFA (5 μM) or SI3-201 (100 μM) with (MM1.RL) or without 
(U266) IL-6 treatment. A nuclear extract from IL-6–stimulated (100 ng/mL) HepG2 cells was used as a positive control. Twenty picomole of either wild-
type AM6 oligonucleotides (WT oligo) or mutant AM6 oligonucleotides (MT oligo) were used as competitive binding controls (see also Experimental 
Procedures). DMSO (0.18%) served as control. Cells were serum-starved (0.1% [w/v] FBS) overnight prior to treatments. Data are representative of two 
(A–C) or three (D) individual experiments; bars, mean ± sem.Yco et al
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than 2 kcal/mol (Fig. 1B). Each conformer was individually 
used in the docking simulations. We also tested a fifth con-
former (generated by local energy minimization), which rep-
resented the approximate average geometry of the canonical 
conformers.
Three STAT3 crystal structures are available, one phos-
phorylated (1BG1) and one nonphosphorylated (4E68) structure, 
each in complex with DNA, and one nonphosphorylated struc-
ture for the unbound protein (3CWG). The STAT3 core pro-
tein encompasses an N-terminal 4-helix coiled-coil structure 
(residues V136-A320), a DNA-binding domain (A406-S514), 
a structurally conserved SH2 domain also frequently found 
in oncoproteins and intracellular signal–transducing proteins 
(T600-R688), and a C-terminal acidic region containing 
phosphorylation sites Y705 and S727 (the latter site is not pres-
ent in the X-ray structure). STAT3 forms a biologically active 
homodimer and we explored possible binding modes both for 
the monomers and the dimers. A total of 100 different dock-
ing scenarios were screened using all possible combinations of 
the five ligand conformers and the various protein receptors 
(monomer/dimer, phosphorylated/nonphosphorylated protein, 
with/without DNA). The docking calculations were performed 
on each scenario by geometric complementarity and semi-flex-
ible docking to take into account inherent receptor flexibility. 
From each run, the 20 lowest energy-docking positions were 
retained which yielded a total of 2000 poses. The presumed 
WFA-binding sites were ranked by conservation score, ie, the 
frequency of occurrence of a residue in a contact area. The con-
tact area was defined as that consisting of the residues within a 
radius of 5 Å centered at the ligand.
Based on the conservation scores of all the residues, we 
identified two main binding locations situated at adjacent areas 
of the SH2 domain. A consensus of five regions constituted the 
first site comprising residues G604-E612 (Rank 1), G587-R595 
(Rank 2), T620-W623 (Rank 3), I634-Y640 (Rank 4), and 
I653-I659 (Rank 5), which formed the sub-pockets of the 
WFA contact areas (Table 1). The absence and presence of 
DNA does not affect the location of the binding sites despite 
the fact that the dimer adopts a distinctly different, locally 
more constrained conformation upon complex formation with 
DNA. Figures 5 and 6 show the binding of WFA to phos-
phorylated and nonphosphorylated STAT3 dimer, in the 
presence and absence of complexed DNA, respectively. Site 1 
is located in a water-accessible surface depression of the SH2 
domain close to the dimerization interface of STAT3 and is 
essentially the same in all structures tested. Both chains were 
found to simultaneously bind ligands in the homodimer. Y705 
was reported earlier to interact with dimerization-disrupting 
small molecules such as S3I-201.106632 (also referred to as 
S3I-201), and WFA bound to Site 1 appears to sit within 5 Å 
from Y705 of the neighboring chain of the dimer near to the 
dimerization interface. Site 1 overlaps but is not necessarily 
entirely identical to the site for interaction with BP-1-102 (see 
Supplementary Fig. 1), an SH2 domain ligand that inhibits 
STAT3 activation and functions in vitro and in vivo.33 Resi-
dues K591, E594, R595, R609, E612, W623, I634, V637, 
E638, and I659 were implicated in computational modeling of 
BP-1-102 binding, and all these residues are also present in the 
ranked sub-pockets of Site 1 (Fig. 7).
The second site covers a broader, more open binding cleft 
and involves residues T708-P715 (Rank 6) and S668-L673 
(Rank 7) (Table 1). It is located near the key site of phosphory-
lation, Y705 from both chains of the dimer (Fig. 6). While 
Site 1 was present in all combinations of the phosphorylated 
receptor–ligand pairs, it was largely absent or its location 
altered in the nonphosphorylated protein. Furthermore, we 
found that Conformer 1 could dock in head and tail orien-
tation at Site 2. The O1 orientation toward the dimerization 
interface appeared more favorable as it occurred with two-
times higher frequency than the reversed position. Sub-pocket 
6 is situated in the immediate vicinity of Y705 of the same 
chain and the proximity of Y705 to WFA was also observed in 
a variety of slightly different binding poses. At any rate, WFA 
binding results in a thermodynamically stable structure that 
leads the dimer to undergo a transition.
Discussion
In this study, we performed a series of cell culture–based 
studies with five NB and two MM tumor cell lines and mea-
sured cell proliferation as well as STAT3 phosphorylation 
and STAT3 transcriptional activation patterns, in the pres-
ence or absence of IL-6 or in cells with constitutively active 
STAT3. Our data showed that WFA induced cell death in a 
dose-dependent manner at significantly lower drug concen-
trations when compared with the STAT3 inhibitor S3I-201. 
At 5.0 μM, WFA induced ~50% cell death in most cell lines 
while S3I-201 at similar concentration had almost no inhibi-
tory potential. Strikingly, cell lines IMR-32 and Be(2)-c, 
which are MYCN-amplified and more aggressive NB sub-
types, were killed most effectively with WFA. While the 
Table 1. summary of docking results with WFA.
SITE 1 CONSENSUS REGIONa
g604-e612 gtFLLRFsE
g587-r595 gFisKerER
t620-W623 tFtW
i634-y640 iQsVEPy
i653-i659 iimgyKI
SITE 2 CONSENSUS REGIONb
t708-P715 tKFicVtP
s668-L673 sPLVyL
Notes: results based on all predictions which include 50 high-resolution 
geometric and 50 low-resolution semi-flexible simulations. aconsensus of 
five regions constitutes the first site, ranked by frequency (conservation) of 
interaction between ligand and protein atoms. bconsensus of two regions 
constitutes a tentative second site. residues presumed to be involved in 
BP-1-102 binding are shown in bold and underlined.Withaferin A inhibits STAT3 in NB and MM cells
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Figure 5. Binding of WFA (Conformer 1) to Y705-phosphorylated STAT3 dimer in complex with DNA (1BG1:V136-F716). Both chains bind ligands 
independently. (A) Site 1, top view. (B) Site 2, top view. (C) Same as a, front view. (D) Same as B, front view. (E) Site 1, close-up front view of the binding 
pocket: g604, t605, F606, L607, t620, F621, t622, W623, Q635, s636, V637, e638, P639, i653, i654, y657, i659, s668, P669, L670, V671, y672, 
L673, K679, P’704, Y’705, L’706 (all residues within 5 Å, residues marked by the prime symbol are from the neighboring chain in the contact area). For 
simplicity and clarity, every tenth residue labels are only displayed along the chain. (F) Site 2, close-up front view of the binding pocket, contact areas: 
g604, F606, L607, F610, F621, t622, W623, Q635, V637, e638, y640, e652, i653, i654, y657, i659, L670, K707, t708, K709, F710, i711, c712, V713, 
t714, P715, L’706, K’707, t’708, K’709, F’71. color scheme for the molecular constituents: green—stAt3 chain A, Amber—stAt3 chain B, yellow—
DnA chain A, Lime—DnA chain B, cyan—y705 in chain A, orange—y705 in chain B, Blue—WFA bound to chain A, red—WFA bound to chain B.
inhibitory effects on MM cell lines were less pronounced, 
WFA at higher concentrations (10 μM) inhibited both MM1.
RL and U266 lines equally at about 50%. In contrast, S3I-201 
only inhibited U266, but not MM1.RL cells, thus suggesting 
that WFA is also effective in a drug-resistant cell type that did 
not respond to S3I-201.
STAT3 phosphorylation at Y705 of untreated and nonin-
duced (control) NB cells was observed in IMR-32 and LAN-5 
but not in Be(2)-c cells and only weakly in SMS-KCNR and 
SH-SY5Y cells. It is possible that of the five NB cell lines 
tested, IMR-32 and LAN-5 express persistently activated 
STAT3, similar to U266 cells. Of note, IMR-32 and LAN-5 
were the two cell lines most potently inhibited by WFA and 
S3I-201, suggesting that STAT3 activity is important in 
those cell lines and contributes to cell proliferation, and cell 
death is effectively induced by both STAT3 inhibitors (Fig. 2). 
WFA successfully inhibited STAT3 phosphorylation in both 
IL-6–induced and persistently activated MM cell lines in 
a time-dependent manner. However, WFA also impacted 
STAT3 and tubulin total protein levels as well as GAPDH 
protein levels (not shown) to various degrees, especially after 
longer (10 hours) exposures, suggesting additional inhibitory 
mechanisms at play that kill cells and are triggered in response 
to WFA and S3I-201 treatments. Interestingly,   subcellular Yco et al
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Figure 6. Binding of WFA (Conformer 2) to nonphosphorylated STAT3 dimer (3CWG:V136-R688). (A) Top view. (B) Front view. (C) Close-up front 
view of the binding pocket: m586, g587, F588, i589, s590, K591, e592, e594, t605, F606, L607, L608, r609, F610, F612, V619, t620, F621, t622, 
W623, I634, Q635, S636, P639, Y640, T641, K642, F647, I651, L670, F683 (all residues within 5 Å). As a matter of clear presentation of the ligand 
neighborhood, the positions of every tenth residue are shown only. the colors are as listed in Figure 5.
separation experiments with cytosolic and nuclear extracts 
of either IL-6–activated MM1.RL or persistently activated 
U266 cells revealed that WFA inhibited the phosphorylation 
of STAT3 at Y705 in both fractions but total STAT3 levels 
declined in the cytosolic fraction and remained consistent or 
slightly increased in the nuclear fraction after WFA treatment. 
This was unexpected since it is known that the inhibition of 
STAT3 phosphorylation at Y705 prevents STAT3 dimeriza-
tion which blocks the subsequent transport of STAT3 to the 
nucleus. Our result suggests that despite the expected absence 
of phosphorylated STAT3 in the nucleus, a fraction of non-
phosphorylated STAT3 is present in the nucleus after WFA 
treatment. It is possible that either nonphosphorylated STAT3 
is transported to the nucleus and/or WFA is transported to 
the nucleus and prevents the phosphorylation of STAT3 in 
the nucleus. Regardless, our experiments with nuclear cell 
extracts showed that the transcriptional activity of STAT3 is 
clearly inhibited by WFA using a highly sensitive, quantitative 
STAT3 transcription factor ELISA (Fig. 4D). Of note, WFA 
inhibited STAT3 transcriptional activity to the same degree 
at a 20-fold lower concentration compared to STAT3 inhibi-
tor S3I-201, thus proposing at least equal target specificity and 
higher drug potency.
While STAT3 inhibition by WFA has been reported in 
other cancer cell systems,34–36 those findings did not reveal 
whether the inhibition of STAT3 activity was due to a direct 
binding of WFA with STAT3. To investigate this, we per-
formed several WFA-STAT3–docking simulations in silico and 
report structure-based evidence in support of a direct molecu-
lar interaction between WFA and STAT3. Furthermore, we 
revealed several key reaction sites of WFA that largely overlap 
with the well-characterized STAT3 inhibitor BP-1-102.33
We first performed computational docking simulations 
to predict the binding site(s) of WFA on STAT3. Our results Withaferin A inhibits STAT3 in NB and MM cells
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Figure 7. Binding of WFA (Conformer 3) to nonphosphorylated STAT3 monomer in complex with DNA (4E68:V136-F716). (A) Site 1, front view. (B) 
Close-up front view of the binding pocket: T527, A529, E530, I580, G587, F588, I589, (K591), (E594), (R595), (R609), F610, (E612), S611, E616, 
G618, V619, T620, (W623), (I634), S636, V637, (V637), E638, (E638), P639, Y640, (I659), W564, A682. As a matter of clear presentation of the ligand 
neighborhood, the positions of every tenth residue are shown only. the dotted surface represents the contact areas for BP-1-102, an inhibitory sh2 
domain ligand and orally available stAt3 inhibitor which largely overlaps with the WFA-binding site. residues presumed to be involved in BP-1-102 
binding are shown in parentheses. the colors are as listed in Figure 5.
showed that two binding interfaces may exist: one primary 
binding site (Site 1) in the SH2 protein domain with high prob-
ability and a tentative secondary site (Site 2) in its neighborhood 
with low probability. SH2 domains typically function as phos-
phorylated tyrosine recognition domains on other proteins thus 
playing a fundamental role in signal transduction. They function 
as regulatory modules of phosphorylation-dependent protein–
protein interactions inducing changes in gene expression and 
other cellular processes. The contact areas of Site 1 include 
Y705, the site of tyrosine phosphorylation from the adjoining 
chain of the protein dimer. Site 2 is located in close proximity 
to Y705 of the same chain and may come proximate to Y705 
from the other chain if binding is accompanied by a conforma-
tional change. Thus, binding of WFA can directly affect phos-
phorylation and coupled signal transduction at any of these two 
sites via changes in physical–chemical factors such as charge, 
hydrogen bonding, solvent accessibility, and side-chain confor-
mations. Ligand reorganization may also play an important role 
in interacting with Y705 and in determining the stability of the 
STAT3 complex with the ligand as all conformers of WFA 
appeared to bind to the protein with decreasing order of occur-
rence from Conformer 1 to Conformer 4. It is plausible that the 
distinctly different conformers undergo a structural transition 
upon binding, resulting in a single active conformer state that 
provides the highest stability for the complex.
A further and more likely mechanism is dimer dis-
ruption. Both sites lie on the same interface of the STAT3 
dimer where they can interrupt or alter dimer formation and 
thereby inhibit normal STAT3 functions similarly to other 
small-molecule inhibitors such as BP-1-102 and S3I-201 (see 
Supplementary Fig. 1). One may speculate that WFA prevents 
the two protein chains from moving into closer proximity 
upon ligand binding and that it would dissociate preexisting 
dimers, thereby arresting the activity of STAT3, as observed 
in experiments depicted in Figure 4D.
Molecular docking further revealed that both chains of 
the dimer can bind ligands simultaneously. However, it is not 
known if sites on both chains must be occupied at the same time 
or binding to only one chain is enough for inhibition of protein 
function. Since the sites are relatively close to each other and are 
close to the dimer interface, there is a possibility that binding at 
only one site is sufficient. Binding may result in some conforma-
tional change rendering the site on the other chain inaccessible, 
or the two chains may actually form one unified binding pocket 
upon a conformational change unless the dimer dissociates.
Site 2 displayed a level of heterogeneity in binding. The 
most probable low-energy binding mode could be determined 
only by scoring and was not obvious from visual inspection. 
This site is not as tight as the primary site as it allows Con-
former 1 to dock in two opposing orientations. This is not 
entirely surprising given that Conformer 1 is a relatively “flat” 
molecule and both its head (O1) and tail (O6) contain a conju-
gated O=C–C=C element and the head/tail moiety can rotate 
relative to each other.
It is important to point out that there are small structural 
variations and missing residues in the vicinity of Site 2 in the 
X-ray structures, which may cause docking simulations to give 
unreliable or spurious results. Therefore, while the location of 
Site 2 near Y705 is an attractive hypothesis, further investiga-
tion is needed and at this point one may consider it as a tenta-
tive possibility.
WFA is one of the most bioactive compounds known 
to exert antiproliferative, proapoptotic, and also anti-
invasive and antiangiogenic effects. It has been associated 
with a number of molecular targets, for example, the pro-
teasome,37–40 Notch-1,41 NF-kB,41,42 cell division cycle 37/Yco et al
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heat shock   protein 90 (Cdc37/HSP90),43 reactive oxygen 
species (ROS),44–46 cyclooxygenase-2 (COX-2),35,46,47 p38 
mitogen-activated protein kinase (p38 MAP kinase),48,49 
AKT/protein kinase B (PKB),41,50 estrogen receptor alpha 
(ER-alpha),51 vimentin,52 vascular endothelial growth fac-
tor (VEGF),53 and acetyl and butyryl cholinesterase.54 
Molecular insights into many of these multifunctional 
activities of WFA and its potential therapeutic effects were 
recently reviewed.20 A wide range of targets and the result-
ing pleiotropic effects are not uncommon in natural product 
research, as exemplified by resveratrol.55,56 Furthermore, a 
number of dietary compounds from nature including capsa-
icin and curcumin have been proposed to interfere with the 
STAT regulatory system.21
However, whether all those reported targets interact 
directly with WFA or are secondary outcomes remains largely 
unknown. For example, it was suggested that the protea-
some is a primary target for WFA;38–40 however, attempts to 
determine the 20S proteasome:WFA complex structure did 
not result in any defined electron density for the natural prod-
uct (data not shown, Michael Groll, Technical University of 
Munich, Germany; personal communication). In contrast, we 
provide in this study first evidence that STAT3 is a direct tar-
get for WFA, which binds in a manner similar to BP-1-102, 
a potent STAT3 inhibitor (Fig. 7), thus strongly supporting 
that WFA is a STAT3 inhibitor that may be further devel-
oped into a useful anticancer therapeutic.
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Supplementary Materials
Supplementary figure 1. Small molecule inhibitors of 
STAT3. (A) BP-1-102, 4-(N-(4-cyclohexylbenzyl)-2-(2,3,4,5, 
6-pentafluoro-N-methylphenylsulfonamido)acetamido)-
2-hydroxybenzoic acid. (B) S3I-201, 2-Hydroxy-4-[[[[(4-
methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid.
Supplementary figure 2. Antiproliferative effect of 
Withaferin A (WFA) in the NCI 60 cell line screen. (A) 
Dose-response curves for WFA. A panel of 60 human tumor 
cell lines representing nine different cancerous tissues of ori-
gin (leukemia, non-small cell lung cancer, colon cancer, CNS 
cancer, melanoma, ovarian cancer, renal cancer, prostate 
cancer, and breast cancer) was tested at the National Can-
cer Institute (NCI) in the presence of WFA at five concen-
trations. WFA was tested over a 10,000-fold concentration 
range in a 2-day assay and exhibited dose-dependent growth 
inhibition to various degrees, in all tested cancer cell lines. 
(B) A Mean Graph display of NCI 60 cell line screening data 
for WFA. Doseresponse data from (A) were used to calculate 
three endpoints for each cell line—GI50 (the log10 of the con-
centration that caused 50% growth inhibition), TGI (the log10 
of the concentration that caused total growth inhibition), and 
LC50 (the log10 of the concentration that caused 50% lethal-
ity). For each endpoint the mean across all the cell lines was 
calculated. The GI50 data are graphed as the difference of the 
GI50 for a particular cell line from the mean GI50. Cell lines 
that are more sensitive are represented as bars deflecting to 
the right of the mean and less sensitive cell lines project to 
the left of the mean. TGI and LC50 Mean Graphs are gener-
ated in a similar fashion. All data are representative of three 
independent evaluation sets (n=3) and were kindly provided 
by the NCI. For additional information about the NCI 60 
cell line panel, see: Shoemaker R. The NCI 60 human tumour 
cell line anticancer drug screen. Nature Reviews   Cancer. 2006; 
6:813–823.
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